Sanofi MS drug tolebrutinib misses goal in relapsing disease trials
Sanofi’s most advanced multiple sclerosis (MS) drug candidate has missed the main goal of two late-stage trials to treat relapsing ...
Read moreTag: CEO Paul Hudson
Popular Post
FRSHAR Mail set to redefine secure communication, data privacy
How to avoid buyer’s remorse when raising venture capital
Microsoft to pay off cloud industry group to end EU antitrust complaint
Capacity utilisation of Pakistan’s cement industry drops to lowest on record
SingTel annual profit more than halves on $2.3bn impairment charge
American Dollar Exchange Rate